Medical Developments International buys back EU rights to Penthrox inhaler from Mundipharma

Medical Developments International (MVP) will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5 million. A 6-month transition period begins September 1, 2020.

“Medical Developments International (MVP) has announced that it will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5 million.”oindpnews.com

• 1 source
• oindpnews.comMedical Developments International buys back European Union rights to Penthrox inhaler from Mundipharma – OINDPnewsAug 1, 2020

Summarized from public sources; check the original articles before acting on it.